PUBLISHER: TechSci Research | PRODUCT CODE: 1881808
PUBLISHER: TechSci Research | PRODUCT CODE: 1881808
We offer 8 hour analyst time for an additional research. Please contact us for the details.
The Global In-vitro Colorectal Cancer Screening Tests Market will grow from USD 890.89 Million in 2024 to USD 1069.98 Million by 2030 at a 3.1% CAGR. In-vitro colorectal cancer screening tests involve diagnostic procedures utilizing biological samples like stool or blood to detect colorectal cancer or its precursors, thereby enabling early disease identification crucial for improved treatment outcomes. The market's growth is primarily driven by the increasing global prevalence of colorectal cancer and heightened awareness regarding early detection methods.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 890.89 Million |
| Market Size 2030 | USD 1069.98 Million |
| CAGR 2025-2030 | 3.1% |
| Fastest Growing Segment | Fecal Occult Blood Tests |
| Largest Market | North America |
Key Market Drivers
The escalating global incidence of colorectal cancer represents a paramount driver for the in-vitro screening tests market. The increasing number of new cases, particularly among younger individuals, highlights a pressing public health demand for accessible and accurate diagnostic tools. This growing disease burden necessitates expanded screening to enable early detection, which is vital for enhancing patient survival and reducing mortality. According to the American Cancer Society, in January 2024, their annual report, "Cancer Statistics, 2024", indicated that colorectal cancer became the leading cause of cancer death in men and the second in women under 50 years old. This escalating incidence directly stimulates demand for improved in-vitro screening methods.
Key Market Challenges
Variable reimbursement policies and the high costs associated with advanced diagnostic technologies present a significant impediment to the expansion of the global in-vitro colorectal cancer screening tests market. These financial barriers restrict patient access to advanced screening options across diverse healthcare systems, particularly when insurance coverage is inconsistent or requires substantial out-of-pocket payments. This directly leads to lower adoption rates, as both healthcare providers and individuals may prioritize more affordable or covered alternatives, even if they are less comprehensive.
Key Market Trends
The growing integration of personalized medicine approaches is a significant trend in colorectal cancer screening, enabling tailored strategies based on individual genetic profiles and risk factors. This facilitates targeted early detection through specific biomarkers. According to the American Cancer Society, in January 2024, their "Cancer Statistics, 2024" report indicated nearly 3% of individuals under 50 diagnosed with colorectal cancer attributed their condition to family history or genetic factors, highlighting the need for individualized screening. Guardant Health, Inc.'s November 2025 report in Current Medical Research and Opinion exemplified this, noting its Shield blood-based screening test achieved 95% patient adherence, showcasing improved compliance with precision diagnostics.
In this report, the Global In-vitro Colorectal Cancer Screening Tests Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies presents in the Global In-vitro Colorectal Cancer Screening Tests Market.
Global In-vitro Colorectal Cancer Screening Tests Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: